Lucille Sebastian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lucille Sebastian has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- David M. Thomas
Centre for Molecular Oncology, School of Biomedical Sciences, University of New South Wales, Kensington, NSW 2033, Australia
4 shared publications - Bruce A. Littlefield
Eisai Inc. 13 , Cambridge, Massachusetts
3 shared publications - David Espinoza
The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia
3 shared publications - Edwin Choy
Mass General Brigham Cancer Institute, Boston, MA
3 shared publications - Emanuele Mazzola
Dana-Farber Cancer Institute 3 Department of Biostatistics and Computational Biology Boston, Massachusetts
3 shared publications - Frank Lin
The Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
3 shared publications
Latest Publications
- 19 August 2026
- Published by Wiley in Internal Medicine Journal
From exclusion to engagement and enrolment: single institutional experience of recruiting Aboriginal and Torres Strait Islander peoples for a genomic sequencing study
Indigenous peoples remain under‐represented in genomic research and clinical trials. This reflects historical exclusion, mistrust and health system barriers. In this article, we describe a single Australian institution's experience in improving engagement and enrolment of Aboriginal and Torres Strait Islander patients in a cancer genomic sequencing study. We reflect on challenges related to rapport, consent and enrolment and outline practical strategies including relationship‐building, targeted resources and a tailored enrolment pathway. We contend that equitable participation in genomic research requires sustained, trust‐based and culturally specific engagement, rather than reliance on purely technical or procedural solutions.
- 19 August 2026
- Published by Wiley in Internal Medicine Journal
From exclusion to engagement and enrolment: single institutional experience of recruiting Aboriginal and Torres Strait Islander peoples for a genomic sequencing study
Indigenous peoples remain under‐represented in genomic research and clinical trials. This reflects historical exclusion, mistrust and health system barriers. In this article, we describe a single Australian institution's experience in improving engagement and enrolment of Aboriginal and Torres Strait Islander patients in a cancer genomic sequencing study. We reflect on challenges related to rapport, consent and enrolment and outline practical strategies including relationship‐building, targeted resources and a tailored enrolment pathway. We contend that equitable participation in genomic research requires sustained, trust‐based and culturally specific engagement, rather than reliance on purely technical or procedural solutions.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose:Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies.Patients and Methods:Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1.Results:Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data.Conclusions:Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.See related commentary by Chen, p. 2130
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose:Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies.Patients and Methods:Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1.Results:Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data.Conclusions:Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.See related commentary by Chen, p. 2130
- 2 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2206-2213
A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies. Patients and Methods: Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Results: Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data. Conclusions: Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity. See related commentary by Chen, p. 2130
- 2 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2206-2213
A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Purpose: Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these vascular sarcomas in a pooled analysis of two parallel phase 2 studies. Patients and Methods: Patients more than age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by RECIST 1.1. Results: Twenty-nine patients were accrued to the study, with 25 (85%) having had prior taxane exposure. We observed an ORR of 17% for angiosarcomas, with 6 of 23 (26%) patients achieving disease stability for greater than 6 months, and an ORR of 33% (2/6) for EHE, with two of six continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared with the immediately prior therapy. Eribulin tolerability was consistent with published data. Conclusions: Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity. See related commentary by Chen, p. 2130